MedTrace Logo

Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris

NCT07345390 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-01-15

No results posted yet for this study

Summary

This study will evaluate the safety, efficacy and pharmacokinetics of KR230109 cream compared with placebo in Patients (18-40 Years) with Acne vulgaris

Conditions

  • Acne Vulgaris

Interventions

DRUG

KR230109 cream 0.025%

KR230109 cream 0.025% is indicated for the topical treatment of acne vulgaris in patients

DRUG

KR230109 cream 0.05%

KR230109 cream 0.05% is indicated for the topical treatment of acne vulgaris in patients

DRUG

Placebo

Vehicle cream manufactured to mimic look and feel of KR230109 Cream but without the active ingredient.

Sponsors & Collaborators

  • Jiangxi Kerui Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-10
Primary Completion
2026-10-30
Completion
2026-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07345390 on ClinicalTrials.gov